Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass.

Fenske WK, Bueter M, Miras AD, Ghatei MA, Bloom SR, le Roux CW

International journal of obesity (2005)21 Jun 2011Cited by 45 (Europe PMC)

PMID21694700DOI10.1038/ijo.2011.126PepBankPUB-21694700

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats after gastric bypass, exendin‑4 further reduced food intake versus saline.
In plain wordsIn rats after gastric bypass, exendin‑4 reduced food intake more than saline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFood intake after bypass
Study
ratn: not reported in source
Roux-en-Y gastric bypass
Comparator
Saline
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
20 nmol kg(-1) · peripheralAs given in this study (rat).
Source sentences
Summary
Administration of both PYY3-36 and Exendin-4 led to a further decrease in food intake in bypass rats compared with saline treatment (P=0.02 and P<0.0001, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of peripheral administration of peptide YY3-36 (PYY3-36; 300 nmol kg(-1)), glucagon-like peptide-1 (GLP-1) analogue Exendin-4 (20 nmol kg(-1)) and somatostatin analogue octreotide (10 μg kg(-1)) on feeding and BW were evaluated in rats after gastric bypass.
Report a problemFND-2169470001
02AnimalAnimal study (in vivo)Efficacy outcome
In sham-operated rats, exendin‑4 reduced food intake versus saline.
In plain wordsIn rats after sham surgery, exendin‑4 reduced food intake more than saline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFood intake after sham surgery
Study
ratn: not reported in source
Sham-operated rats
Comparator
Saline
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
20 nmol kg(-1) · peripheralAs given in this study (rat).
Source sentences
Summary
Similar reduction in food intake was observed in sham rats (P=0.02 and P<0.001, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Administration of both PYY3-36 and Exendin-4 led to a further decrease in food intake in bypass rats compared with saline treatment (P=0.02 and P<0.0001, respectively).
Summary · context
The effects of peripheral administration of peptide YY3-36 (PYY3-36; 300 nmol kg(-1)), glucagon-like peptide-1 (GLP-1) analogue Exendin-4 (20 nmol kg(-1)) and somatostatin analogue octreotide (10 μg kg(-1)) on feeding and BW were evaluated in rats after gastric bypass.
Report a problemFND-2169470002
03AnimalAnimal study (in vivo)Efficacy outcome
In rats after gastric bypass, exendin‑4 produced significant body weight loss.
In plain wordsIn rats after gastric bypass, exendin‑4 produced significant weight loss.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight after bypass
Study
ratn: not reported in source
Roux-en-Y gastric bypass
Outcome group
Body weight · Metabolic and weight
Studied dose
20 nmol kg(-1) · peripheralAs given in this study (rat).
Source sentences
Summary
Exendin-4 treatment resulted in a significant BW loss in bypass (P=0.03) and sham rats (P=0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of peripheral administration of peptide YY3-36 (PYY3-36; 300 nmol kg(-1)), glucagon-like peptide-1 (GLP-1) analogue Exendin-4 (20 nmol kg(-1)) and somatostatin analogue octreotide (10 μg kg(-1)) on feeding and BW were evaluated in rats after gastric bypass.
Report a problemFND-2169470003
04AnimalAnimal study (in vivo)Efficacy outcome
In sham-operated rats, exendin‑4 produced significant body weight loss.
In plain wordsIn rats after sham surgery, exendin‑4 produced significant weight loss.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight after sham surgery
Study
ratn: not reported in source
Sham-operated rats
Outcome group
Body weight · Metabolic and weight
Studied dose
20 nmol kg(-1) · peripheralAs given in this study (rat).
Source sentences
Summary
Exendin-4 treatment resulted in a significant BW loss in bypass (P=0.03) and sham rats (P=0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of peripheral administration of peptide YY3-36 (PYY3-36; 300 nmol kg(-1)), glucagon-like peptide-1 (GLP-1) analogue Exendin-4 (20 nmol kg(-1)) and somatostatin analogue octreotide (10 μg kg(-1)) on feeding and BW were evaluated in rats after gastric bypass.
Report a problemFND-2169470004
05AnimalAnimal study (in vivo)Efficacy outcome
In rats after gastric bypass, subsequent octreotide treatment increased food intake (P=0.007).
In plain wordsIn rats after gastric bypass, subsequent octreotide treatment increased food intake.
Peptide
Octreotide
Outcome
IncreaseFood intake after gastric bypass
Study
ratn: not reported in source
Rats after Roux-en-Y gastric bypass
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
10 μg kg(-1) · peripheralAs given in this study (rat).
Measurements
P value
0.007
food intake in bypass rats
Source sentences
Summary
Subsequent treatment with octreotide led to an increase in food intake in bypass (P=0.007)
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of peripheral administration of peptide YY3-36 (PYY3-36; 300 nmol kg(-1)), glucagon-like peptide-1 (GLP-1) analogue Exendin-4 (20 nmol kg(-1)) and somatostatin analogue octreotide (10 μg kg(-1)) on feeding and BW were evaluated in rats after gastric bypass.
Report a problemFND-2169470005
06AnimalAnimal study (in vivo)Efficacy outcome
In sham-operated rats, subsequent octreotide treatment did not significantly increase food intake (P=0.87).
In plain wordsIn sham-operated rats, subsequent octreotide treatment did not significantly increase food intake.
Peptide
Octreotide
Outcome
No significant changeFood intake after sham operation
Study
ratn: not reported in source
Sham-operated rats
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
10 μg kg(-1) · peripheralAs given in this study (rat).
Measurements
P value
0.87
food intake in sham rats
Source sentences
Summary
Subsequent treatment with octreotide led to an increase in food intake in bypass (P=0.007), but not in sham rats (P=0.87).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of peripheral administration of peptide YY3-36 (PYY3-36; 300 nmol kg(-1)), glucagon-like peptide-1 (GLP-1) analogue Exendin-4 (20 nmol kg(-1)) and somatostatin analogue octreotide (10 μg kg(-1)) on feeding and BW were evaluated in rats after gastric bypass.
Report a problemFND-2169470006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.